Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery
The last decade has witnessed developments in the CF drug pipeline which are both exciting and unprecedented, bringing with them previously unconsidered challenges. The Task Force group was brought together to consider these challenges and possible strategies to address them. Over the last 18 months, we have discussed internally and gathered views from a broad range of individuals representing patient organisations, clinical and research teams, the pharmaceutical industry and regulatory agencies.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Jane C. Davies, Pavel Drevinek, J. Stuart Elborn, Eitan Kerem, Tim Lee, On behalf of the European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF’, Margarida D. Amaral, Kris de Boeck, Jane C. Davies, Pavel Tags: Original Article Source Type: research